Search Results

You are looking at 71 - 80 of 190 items for :

  • "Renal cell carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Renal Cell Cancer: A Shift in Approaches for Treatment of Advanced Disease in the United States

Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann, and K. Robin Yabroff

. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma . N Engl J Med 2007 ; 356 : 115 – 124 . 3. Cohen HT McGovern FJ . Renal-cell carcinoma . N Engl J Med 2005 ; 353 : 2477 – 2490 . 4. Hutson TE . Targeted

Full access

NCCN News

-based initiatives to improve patient care and outcomes in renal cell carcinoma and hematologic malignancies. The intent of the RFP is to encourage academic and community-based organizations to submit proposals describing concepts and ideas for design and

Full access

HSR24-144: Does Immunotherapy Work in Patients With Poor Performance Status?

Maya Gogtay, Omar Khaled Abughanimeh, and Benjamin A. Teply

. Group B had a mean age of 55.88 years, 56% were males, 88% Caucasians with 40% receiving the combination ICI as first line treatment. The most common cancers were melanoma followed by renal cell carcinoma. Disease control rates were 60% for Group A (N=19

Full access

CLO24-070: Partial Versus Radical Nephrectomy: An Age-Wise Comparison of the National Cancer Database

Dianelis Gonzalez Pupo, Daniel Boaretto, Armin Ghomeshi, Dominique Lopez, Pushan Prabhakar, Arjun Pon Avudaiappan, Ahmed Eldefrawy, Murugesan Manoharan, and Jorge Caso

) to compare PN versus RN and clinical factors stratified by age. Methods: The NCDB was queries for patients with clinical stage T1-T2N0M0 patients with renal cell carcinoma who received a PN or RN. These patients were then further stratified by age

Full access

CLO24-073: Contemporary Treatment Patterns for Patients Diagnosed With cT1a Renal Tumors: A National Cancer Database Study

Dominique Lopez, Aden Swayze, Armin Ghomeshi, Nathan VanderVeer-Harris, Pushan Prabhakar, Arjun Pon Avudaiappan, Ahmed Eldefrawy, Murugesan Manoharan, and Jorge Caso

in T1a renal cell carcinoma (RCC). Methods: Patients with kidney tumors were identified in the National Cancer Database (NCDB) between 2004 and 2020. A total of 720,941 patients were found in the initial cohort. Out of these, patients with a

Full access

YIA24-006: The NF-I/a Transcription Factor is a HIF-Independent Oncogenic Dependency in Kidney Cancer

Jason Scovell, Shannon Zayas, Treg Grubb, Fengshen Kuo, Eduard Reznik, A. Ari Hakimi, and Abhishek Chakraborty

Background: Clear Cell Renal Cell Carcinoma (ccRCC), the predominant form of adult kidney cancer, is incurable in advanced stages despite recent clinical advances. New therapeutic targets that can complement existing treatment options (e

Full access

EPR21-035: Immune Checkpoint Inhibitor-Related Hemophagocytic Lymphohistiocytosis: A Food and Drug Association Adverse Event Reporting System (FAERS) Analysis

Udhayvir Singh Grewal, Sahith Reddy Thotamgari, Shiva Jashwanth Gaddam, Jasmeen Kaur Uppal, Parth Rajeshbhai Shah, and Cesar Davila-Chapa

.5%). Median age of the patients was 65 years (IQR 52,71). Malignant melanoma (MM) was the most common malignancy identified (69/199, 34.6%) followed by non-small cell lung cancer/NSCLC (61/199, 30.6%) and renal cell carcinoma/RCC (12/199, 6%). Highest number

Full access

Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805

Wendy J. Bottinor, Yael Flamand, Naomi B. Haas, Anne M. ONeill, Robert S. DiPaola, Pearl Subramanian, David Cella, W. Gregory Hundley, Lynne I. Wagner, John M. Salsman, and Bonnie Ky

research, with a significant CVD burden. Our study specifically examines the influence of VEGFi therapy (sunitinib and sorafenib) on LVSD and blood pressure among AYAs undergoing adjuvant therapy for unfavorable, high-risk renal cell carcinoma. Our main

Full access

Multidisciplinary Management of Advanced Kidney Cancer

Presented by: Chad A. LaGrange, M. Dror Michaelson, and Colleen H. Tetzlaff

. Imaging revealed multiple renal masses in the right kidney near the right renal vein and small masses in the left kidney. His workup revealed no lung or brain metastases. Biopsy of the humerus confirmed that he had clear-cell renal cell carcinoma (RCC). He

Full access

Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor

Eleonora Pelle, Taymeyah Al-Toubah, Brian Morse, and Jonathan Strosberg

tumors in multiple organs, including multifocal central nervous system (CNS) hemangioblastomas, renal cell carcinomas (RCCs), pheochromocytomas, and pancreatic neuroendocrine tumors (pNETs). 4 , 10 Belzutifan is a second-generation small molecule that